Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioavailability and Food Effect of Mevrometostat in Healthy Participants
NCT05767905Phase 1Completed
- Sponsor
- Pfizer
- Start
- Mar 2023
- Primary completion
- Jun 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of mevrometostat in prostate cancer (PCa) (3 arms), sponsored by Pfizer. Primary endpoints: Area Under the Plasma Concentration-time Profile From Time 0 Extrapolated to Infinite Time and Maximum Plasma Concentration. Started Mar 2023; status: completed.
02
Drugs
mevrometostat
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT05767905.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05767905.